TGFB1 and cancer: AP in cancer cells by increasing the secretion of cytokines and immune modulatory factors, including IL6, IL10, TGFβ, and VEGF, and activating survival/signaling pathways such as PI3K-Akt-mTOR, sustains immunosuppression and promotes tumor progression, metastasis, and therapy resistance [26,129,130].